Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147M
-
Number of holders
-
208
-
Total 13F shares, excl. options
-
121M
-
Shares change
-
+6.33M
-
Total reported value, excl. options
-
$2.49B
-
Value change
-
+$125M
-
Put/Call ratio
-
0.98
-
Number of buys
-
105
-
Number of sells
-
-99
-
Price
-
$20.52
Significant Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q1 2024
254 filings reported holding DNLI - Denali Therapeutics Inc. - COMMON STOCK as of Q1 2024.
Denali Therapeutics Inc. - COMMON STOCK (DNLI) has 208 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 121M shares
of 147M outstanding shares and own 82.3% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (14M shares), BlackRock Inc. (12.2M shares), VANGUARD GROUP INC (11M shares), WELLINGTON MANAGEMENT GROUP LLP (8.27M shares), STATE STREET CORP (6.32M shares), Capital Research Global Investors (6.05M shares), Temasek Holdings (Private) Ltd (5.71M shares), Crestline Management, LP (5.21M shares), TAKEDA PHARMACEUTICAL CO LTD (4.21M shares), and BAKER BROS. ADVISORS LP (3.73M shares).
This table shows the top 208 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.